vs
Side-by-side financial comparison of EverQuote, Inc. (EVER) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $195.3M, roughly 1.5× EverQuote, Inc.). EverQuote, Inc. runs the higher net margin — 29.6% vs 12.8%, a 16.7% gap on every dollar of revenue. On growth, EverQuote, Inc. posted the faster year-over-year revenue change (32.5% vs -6.4%). Over the past eight quarters, EverQuote, Inc.'s revenue compounded faster (29.1% CAGR vs 4.2%).
EverQuote, Inc. is an online insurance marketplace founded in 2011 and based in Cambridge, Massachusetts.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
EVER vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $195.3M | $295.9M |
| Net Profit | $57.8M | $38.0M |
| Gross Margin | 97.7% | 64.6% |
| Operating Margin | 9.5% | 18.4% |
| Net Margin | 29.6% | 12.8% |
| Revenue YoY | 32.5% | -6.4% |
| Net Profit YoY | 369.3% | 68.3% |
| EPS (diluted) | $1.54 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $195.3M | — | ||
| Q4 25 | $195.3M | $295.9M | ||
| Q3 25 | $173.9M | — | ||
| Q2 25 | $156.6M | $317.0M | ||
| Q1 25 | $166.6M | $316.2M | ||
| Q4 24 | $147.5M | $297.0M | ||
| Q3 24 | $144.5M | $289.5M | ||
| Q2 24 | $117.1M | $306.1M |
| Q1 26 | $57.8M | — | ||
| Q4 25 | $57.8M | $38.0M | ||
| Q3 25 | $18.9M | — | ||
| Q2 25 | $14.7M | $-17.7M | ||
| Q1 25 | $8.0M | $22.6M | ||
| Q4 24 | $12.3M | $34.9M | ||
| Q3 24 | $11.6M | $33.6M | ||
| Q2 24 | $6.4M | $40.6M |
| Q1 26 | 97.7% | — | ||
| Q4 25 | 97.7% | 64.6% | ||
| Q3 25 | 97.3% | — | ||
| Q2 25 | 96.9% | 62.7% | ||
| Q1 25 | 96.8% | 67.9% | ||
| Q4 24 | 96.3% | 65.3% | ||
| Q3 24 | 96.2% | 63.2% | ||
| Q2 24 | 95.7% | 66.4% |
| Q1 26 | 9.5% | — | ||
| Q4 25 | 9.5% | 18.4% | ||
| Q3 25 | 10.1% | — | ||
| Q2 25 | 9.0% | -7.5% | ||
| Q1 25 | 4.8% | 12.2% | ||
| Q4 24 | 8.2% | 16.0% | ||
| Q3 24 | 8.1% | 13.8% | ||
| Q2 24 | 5.4% | 15.0% |
| Q1 26 | 29.6% | — | ||
| Q4 25 | 29.6% | 12.8% | ||
| Q3 25 | 10.8% | — | ||
| Q2 25 | 9.4% | -5.6% | ||
| Q1 25 | 4.8% | 7.1% | ||
| Q4 24 | 8.3% | 11.7% | ||
| Q3 24 | 8.0% | 11.6% | ||
| Q2 24 | 5.5% | 13.3% |
| Q1 26 | $1.54 | — | ||
| Q4 25 | $1.53 | $0.24 | ||
| Q3 25 | $0.50 | — | ||
| Q2 25 | $0.39 | $-0.11 | ||
| Q1 25 | $0.21 | $0.14 | ||
| Q4 24 | $0.35 | $0.22 | ||
| Q3 24 | $0.31 | $0.21 | ||
| Q2 24 | $0.17 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $171.4M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $238.0M | $2.0B |
| Total Assets | $326.9M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $171.4M | — | ||
| Q4 25 | $171.4M | $172.9M | ||
| Q3 25 | $145.8M | — | ||
| Q2 25 | $148.2M | $162.2M | ||
| Q1 25 | $125.0M | $140.7M | ||
| Q4 24 | $102.1M | $177.5M | ||
| Q3 24 | $82.8M | $187.5M | ||
| Q2 24 | $60.9M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $238.0M | — | ||
| Q4 25 | $238.0M | $2.0B | ||
| Q3 25 | $174.9M | — | ||
| Q2 25 | $170.3M | $1.9B | ||
| Q1 25 | $149.5M | $2.0B | ||
| Q4 24 | $135.4M | $2.1B | ||
| Q3 24 | $117.7M | $2.1B | ||
| Q2 24 | $100.8M | $2.1B |
| Q1 26 | $326.9M | — | ||
| Q4 25 | $326.9M | $2.5B | ||
| Q3 25 | $256.1M | — | ||
| Q2 25 | $241.4M | $2.6B | ||
| Q1 25 | $232.1M | $2.6B | ||
| Q4 24 | $210.5M | $2.7B | ||
| Q3 24 | $180.5M | $2.7B | ||
| Q2 24 | $158.0M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $27.0M | — | ||
| Q4 25 | $27.0M | — | ||
| Q3 25 | $19.8M | — | ||
| Q2 25 | $25.3M | $98.2M | ||
| Q1 25 | $23.3M | $41.1M | ||
| Q4 24 | $20.1M | $84.3M | ||
| Q3 24 | $23.6M | $63.9M | ||
| Q2 24 | $12.4M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $25.8M | — | ||
| Q3 25 | $18.5M | — | ||
| Q2 25 | $23.8M | $93.3M | ||
| Q1 25 | $22.2M | $31.0M | ||
| Q4 24 | $19.1M | $77.5M | ||
| Q3 24 | $22.1M | $54.7M | ||
| Q2 24 | $11.5M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | 13.2% | — | ||
| Q3 25 | 10.6% | — | ||
| Q2 25 | 15.2% | 29.4% | ||
| Q1 25 | 13.3% | 9.8% | ||
| Q4 24 | 13.0% | 26.1% | ||
| Q3 24 | 15.3% | 18.9% | ||
| Q2 24 | 9.8% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 0.7% | 3.2% | ||
| Q4 24 | 0.7% | 2.3% | ||
| Q3 24 | 1.0% | 3.2% | ||
| Q2 24 | 0.7% | 5.9% |
| Q1 26 | 0.47× | — | ||
| Q4 25 | 0.47× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 2.92× | 1.82× | ||
| Q4 24 | 1.64× | 2.42× | ||
| Q3 24 | 2.04× | 1.90× | ||
| Q2 24 | 1.93× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVER
| Automotive | $179.9M | 92% |
| Home and renters | $15.4M | 8% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
